Deutschland
- Deutsch
España
- Español
Italia
- ItalianoOur Products
Grünenthal Meds provides treatments for patients suffering with a range of conditions, including opioid-induced constipation, chronic anal fissure, breakthrough cancer pain, chemotherapy-induced nausea and vomiting, vitamin D deficiency and vitamin deficiency.
Click on the links below to learn more about these conditions and the ways in which we can help you treat them.
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App store.
Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000.Bone Health
Vitamin D Deficiency
Provided by
KKI NewCo (known as Grünenthal Meds)
Stexerol-D3 is indicated in adults, the elderly and adolescents for prevention and treatment of vitamin D deficiency, or as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.1
Click here for prescribing and adverse event reporting information.
Gastrointestinal
OPIOID-INDUCED CONSTIPATION
Provided by
KKI NewCo (known as Grünenthal Meds)
MOVENTIG is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).2
Click here for prescribing and adverse event reporting information.
CHRONIC ANAL FISSURE
Provided by
KKI NewCo (known as Grünenthal Meds)
RECTOGESIC® 4 mg/g Rectal Ointment is indicated in adults for relief of pain associated with chronic anal fissure.3
Click here for prescribing and adverse event reporting information.
Oncology
BREAKTHROUGH CANCER PAIN
Provided by
KKI NewCo (known as Grünenthal Meds)
Abstral® is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.4
Click here for prescribing and adverse event reporting information.
BREAKTHROUGH CANCER PAIN
Provided by
KKI NewCo (known as Grünenthal Meds)
PecFent® is indicated for the management of breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.5
Click here for prescribing and adverse event reporting information.
Chemotherapy-induced Nausea and Vomiting
Provided by
KKI NewCo (known as Grünenthal Meds)
SANCUSO transdermal patch is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic multi-day chemotherapy in adult patients with swallowing difficulties.6
Click here for prescribing and adverse event reporting information.
Vitamin Deficiency
ALCOHOL-RELATED BRAIN DAMAGE (ARBD)
Provided by
KKI NewCo (known as Grünenthal Meds)
Vitamins B&C Kyowa Kirin Intravenous High Potency, Concentrate for Solution for Infusion is indicated in adults and children for rapid therapy of severe depletion or malabsorption of the water soluble vitamins B and C:7
Click here for prescribing and adverse event reporting information.
-
References
1. Stexerol-D3® (colecalciferol) Summary of Product Characteristics.
2. MOVENTIG® (naloxegol). Summary of Product Characteristics.
3. RECTOGESIC® (glyceryl trinitrate) Summary of Product Characteristics.
4. Abstral® (fentanyl citrate) Summary of Product Characteristics.
5. PecFent® (fentanyl citrate) Summary of Product Characteristics.
6. SANCUSO® (granisetron) Summary of Product Characteristics.
7. Vitamins B&C Kyowa Kirin Intravenous High Potency, Concentrate for Solution for Infusion (vitamins B & C) Summary of Product Characteristics.
KKI/UK/GEN/0120 June 2024